Enanta Pharmaceuticals (NASDAQ:ENTA) PT Lowered to $22.00

Enanta Pharmaceuticals (NASDAQ:ENTA) had its target price decreased by analysts at JMP Securities from $23.00 to $22.00 in a research note issued on Tuesday, Benzinga reports. The firm presently has a “market outperform” rating on the biotechnology company’s stock. JMP Securities’ price objective would indicate a potential upside of 72.41% from the company’s previous close.

Other equities research analysts have also issued research reports about the company. JPMorgan Chase & Co. reduced their price target on Enanta Pharmaceuticals from $12.00 to $11.00 and set an “underweight” rating on the stock in a research report on Thursday, February 8th. StockNews.com cut shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, April 6th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, Enanta Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $19.00.

Enanta Pharmaceuticals Stock Down 2.6 %

Enanta Pharmaceuticals stock opened at $12.76 on Tuesday. Enanta Pharmaceuticals has a 52-week low of $8.08 and a 52-week high of $28.25. The firm has a market cap of $269.95 million, a PE ratio of -2.04 and a beta of 0.54. The company’s 50 day moving average is $14.88 and its two-hundred day moving average is $12.08.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.18) by ($0.40). The company had revenue of $18.00 million during the quarter, compared to analyst estimates of $22.74 million. Enanta Pharmaceuticals had a negative net margin of 187.77% and a negative return on equity of 60.38%. On average, equities research analysts anticipate that Enanta Pharmaceuticals will post -4.9 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Enanta Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Acadian Asset Management LLC lifted its position in shares of Enanta Pharmaceuticals by 445.6% during the 3rd quarter. Acadian Asset Management LLC now owns 548,782 shares of the biotechnology company’s stock worth $6,125,000 after buying an additional 448,201 shares during the last quarter. Assenagon Asset Management S.A. boosted its stake in Enanta Pharmaceuticals by 613.6% in the third quarter. Assenagon Asset Management S.A. now owns 631,626 shares of the biotechnology company’s stock valued at $7,055,000 after acquiring an additional 543,111 shares in the last quarter. Federated Hermes Inc. purchased a new position in shares of Enanta Pharmaceuticals during the fourth quarter worth about $1,253,000. Walleye Capital LLC increased its position in shares of Enanta Pharmaceuticals by 342.8% during the third quarter. Walleye Capital LLC now owns 119,364 shares of the biotechnology company’s stock worth $1,333,000 after purchasing an additional 92,410 shares in the last quarter. Finally, Trexquant Investment LP purchased a new stake in shares of Enanta Pharmaceuticals in the 3rd quarter valued at about $1,481,000. 94.99% of the stock is owned by institutional investors and hedge funds.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.